MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer at the AACR IO Annual Meeting, February 23-26 in Los Angeles. The presentation, titled “Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC),” is scheduled for Tuesday, February 25th. This research focuses on evaluating the efficacy of this combination therapy in patients who have not responded to previous treatments, highlighting MiNK’s commitment to developing novel cancer therapies.
This data release is crucial for several reasons. Gastric cancer remains a significant unmet medical need, with limited effective treatment options for patients who progress after initial therapies. The combination of AgenT-797 with existing immunotherapies like botensilimab and balstilimab represents a potentially promising new approach, leveraging the unique properties of iNKT cells to enhance anti-tumor responses. Positive interim data could validate MiNK’s iNKT platform and generate excitement for its potential application in other difficult-to-treat cancers.
The Phase 2 trial investigates AgenT-797, an allogeneic, off-the-shelf iNKT cell therapy. It works by harnessing the power of iNKT cells, immune cells with both cytotoxic and adaptive properties, making them potent activators of the immune system. The study combines AgenT-797 with botensilimab, a CTLA-4 inhibitor, and balstilimab, a PD-1 inhibitor, aiming to synergistically enhance the anti-tumor immune response in patients with refractory gastric cancer. The upcoming presentation will focus on biomarker analysis, providing insights into the biological mechanisms underlying the treatment’s effects and potentially identifying predictive biomarkers for patient selection.
Positive interim data from this Phase 2 trial could significantly advance MiNK’s position in the immuno-oncology space. It would provide clinical validation for their iNKT cell therapy platform and could attract further investment and partnerships. Furthermore, it could pave the way for larger clinical trials and potentially accelerate the development of AgenT-797 for this and other cancer indications. The results may also stimulate further research into iNKT cell therapies, opening up new avenues for cancer treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
